Allison Transmission Holdings Inc. announced it will release its third quarter 2026 financial results on November 2, 2026, after market close. The company will hold a conference call at 5:00 p.m. EST the same day to discuss its financial performance. Investors can join via phone or live webcast, with a replay available for two weeks. This event provides insight into Allison's business health and outlook in industrial mobility and work solutions.
Allison Transmission's upcoming Q3 2026 earnings call is noted here with Industrials sector data from Pluang as of Oct 20, 2026 03:01 WIB. Among 135 Industrials stocks, 46 rose and 88 fell. Enovix Corporation (ENVX) traded at USD 2.35 with a 1-day change of -5.62% and a typical hold time of 11 days, contrasting with United Airlines Holdings (UAL) at USD 96.13, down 5.11% with 99% sell orders and a 46-day hold time, and Delta Air Lines (DAL) at USD 75.28, down 3.59% with similar sell pressure but a longer hold time of 98 days.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
